Sensitivity to cultural context is one of the keys to successful patient education and communication. An innovative program has met with success in encouraging women of Asian-Indio descent to participate in cancer screenings.
Nurse and patient navigators from all over the country attended the Academy of Oncology Nurse & Patient Navigators (AONN+) 2017 West Coast Regional Meeting in April. The meeting provided a forum for open dialogue around navigation and survivorship care services for patients with cancer, fostered lively discussions regarding the complexities of cancer care in the rapidly growing field of navigation, and led to new ideas for the improved delivery of navigation and survivorship care services.
Obesity is about to overtake tobacco as a modifiable risk factor for cancer. Approximately 30% of cancers could be prevented by maintaining a normal weight and healthy lifestyle, according to 2 experts who spoke at the 42nd annual meeting of the Oncology Nursing Society.
Chimeric antigen receptor T-cell (CAR-T) therapy has revolutionized the treatment of some hematologic malignancies. This treatment is still investigational, and none of the CAR T-cell products being studied have received FDA approval yet, but approval is expected soon.
In recognition of the distress associated with the diagnosis and treatment of cancer, the National Comprehensive Cancer Network (NCCN) has produced several resources to help patients report their distress and cope with it.
Chimeric antigen receptor T-cell therapy is an immunotherapeutic approach that has yielded favorable outcomes in various hematologic malignancies. Educating oncology nurses on how to recognize serious adverse events, such as cytokine release syndrome (CRS), is critical for early intervention and reducing CRS-related deaths.
Breast cancer is the second leading cause of cancer-related deaths in women in the United States. Despite the increase in survival with trastuzumab in the adjuvant setting, up to 26% of patients with early-stage HER2+ breast cancer experience disease recurrence within 5 to 8 years. The interim analysis after 5 years of follow-up in the ExteNET trial is presented.